CURATIS N AG (CURN) - Cash Flow Conversion Efficiency

Latest as of June 2025: -0.024x

Based on the latest financial reports, CURATIS N AG (CURN) has a cash flow conversion efficiency ratio of -0.024x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF-1.05 Million ≈ $-1.33 Million USD) by net assets (CHF44.56 Million ≈ $56.34 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CURATIS N AG (CURN) net asset quality to measure how much of total assets are equity-financed.

CURATIS N AG - Cash Flow Conversion Efficiency Trend (2002–2024)

This chart illustrates how CURATIS N AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check CURATIS N AG cash earnings quality to evaluate the quality of earnings relative to operating cash generation.

CURATIS N AG Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of CURATIS N AG ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Inseego Corp
NASDAQ:INSG
-0.067x
Indorama Synthetics Tbk
JK:INDR
0.014x
BIOCELTIX S.A. ZY -10
F:XI3
-0.062x
Metro Ticari ve Mali Yatirimlar Holding AS
IS:METRO
0.000x
MMP Industries Limited
NSE:MMP
0.079x
Fast Ejendom
CO:FED
0.010x
e-LITECOM CO. Ltd
KQ:041520
-0.006x
ÖKOWORLD AG
XETRA:VVV3
0.008x

Annual Cash Flow Conversion Efficiency for CURATIS N AG (2002–2024)

The table below shows the annual cash flow conversion efficiency of CURATIS N AG from 2002 to 2024. For the full company profile with market capitalisation and key ratios, see CURN company net worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 CHF45.60 Million
≈ $57.65 Million
CHF-825.00K
≈ $-1.04 Million
-0.018x -100.30%
2023-12-31 CHF-312.00K
≈ $-394.45K
CHF-1.89 Million
≈ $-2.38 Million
6.042x +976.84%
2022-12-31 CHF6.75 Million
≈ $8.54 Million
CHF-4.65 Million
≈ $-5.88 Million
-0.689x -176.77%
2021-12-31 CHF-400.00K
≈ $-505.71K
CHF-359.00K
≈ $-453.87K
0.898x -38.98%
2020-12-31 CHF-257.00K
≈ $-324.92K
CHF-378.00K
≈ $-477.89K
1.471x +22.64%
2019-12-31 CHF-552.00K
≈ $-697.88K
CHF-662.00K
≈ $-836.95K
1.199x +160.36%
2018-12-31 CHF377.00K
≈ $476.63K
CHF-749.00K
≈ $-946.94K
-1.987x -7596.73%
2017-12-31 CHF4.68 Million
≈ $5.92 Million
CHF124.00K
≈ $156.77K
0.027x +273.50%
2016-12-31 CHF5.04 Million
≈ $6.37 Million
CHF-77.00K
≈ $-97.35K
-0.015x +23.75%
2015-12-31 CHF6.24 Million
≈ $7.89 Million
CHF-125.00K
≈ $-158.03K
-0.020x -34.08%
2014-12-31 CHF7.90 Million
≈ $9.99 Million
CHF-118.00K
≈ $-149.18K
-0.015x +92.26%
2013-12-31 CHF8.71 Million
≈ $11.01 Million
CHF-1.68 Million
≈ $-2.12 Million
-0.193x -445.52%
2012-12-31 CHF11.60 Million
≈ $14.67 Million
CHF648.00K
≈ $819.25K
0.056x +32.82%
2011-12-31 CHF7.16 Million
≈ $9.05 Million
CHF301.00K
≈ $380.55K
0.042x -82.42%
2010-12-31 CHF6.98 Million
≈ $8.82 Million
CHF1.67 Million
≈ $2.11 Million
0.239x +41.54%
2009-12-31 CHF5.88 Million
≈ $7.44 Million
CHF994.00K
≈ $1.26 Million
0.169x +105.69%
2008-12-31 CHF1.64 Million
≈ $2.08 Million
CHF-4.88 Million
≈ $-6.16 Million
-2.968x +90.51%
2007-12-31 CHF227.00K
≈ $286.99K
CHF-7.10 Million
≈ $-8.98 Million
-31.282x -10014.42%
2006-12-31 CHF9.30 Million
≈ $11.76 Million
CHF-2.88 Million
≈ $-3.64 Million
-0.309x -27.63%
2005-12-31 CHF21.67 Million
≈ $27.40 Million
CHF-5.25 Million
≈ $-6.64 Million
-0.242x -801.22%
2004-12-31 CHF37.30 Million
≈ $47.16 Million
CHF1.29 Million
≈ $1.63 Million
0.035x +188.13%
2003-12-31 CHF49.83 Million
≈ $63.00 Million
CHF-1.95 Million
≈ $-2.47 Million
-0.039x +89.09%
2002-12-31 CHF55.33 Million
≈ $69.96 Million
CHF-19.88 Million
≈ $-25.13 Million
-0.359x --

About CURATIS N AG

SW:CURN Switzerland Drug Manufacturers - Specialty & Generic
Market Cap
$130.26 Million
CHF103.03 Million CHF
Market Cap Rank
#19608 Global
#189 in Switzerland
Share Price
CHF20.00
Change (1 day)
-1.48%
52-Week Range
CHF11.05 - CHF26.00
All Time High
CHF891.52
About

Curatis Holding AG engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases. It offers its products in the areas of fentanyl, breakthrough pain, antiplatelet, metastatic hormone receptor-positive breast cancer, anti-arrhythmic, nasal oil, wilson's disease, cyanide poisoning, digoxin toxicity, antih… Read more